FDA approves AstraZeneca breast cancer drug despite negative advisory committee vote; Novartis faces cholesterol drug setbacks

The U.S. Food and Drug Administration granted approval to AstraZeneca's breast cancer therapy even though the advisory committee voted against it. The decision underscores the agency's willingness to move forward despite dissenting expert opinions.

The approval came after a negative recommendation from the advisory panel, highlighting a split between regulatory judgment and advisory consensus. Details on the drug's efficacy or safety profile were not provided in the brief source.

In a separate development, Novartis encountered setbacks with its pipeline of drugs aimed at cholesterol management. The specific nature of these challenges was not disclosed, but they signal potential hurdles for the company's cardiovascular portfolio.

Overall, the regulatory landscape shows both advancement for some products and obstacles for others, reflecting the complex dynamics of drug development and approval.